Intech Investment Management LLC Acquires 53,282 Shares of Artivion, Inc. $AORT

Intech Investment Management LLC lifted its holdings in Artivion, Inc. (NYSE:AORT) by 268.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 73,104 shares of the company’s stock after buying an additional 53,282 shares during the quarter. Intech Investment Management LLC’s holdings in Artivion were worth $3,334,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Caitong International Asset Management Co. Ltd bought a new position in Artivion in the third quarter valued at approximately $27,000. Aster Capital Management DIFC Ltd boosted its stake in Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after purchasing an additional 519 shares during the period. Larson Financial Group LLC boosted its stake in Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares during the period. USA Financial Formulas increased its holdings in Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after purchasing an additional 703 shares in the last quarter. Finally, KBC Group NV bought a new position in Artivion during the 4th quarter worth about $65,000. 86.37% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Artivion news, SVP Jean F. Holloway sold 8,962 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $38.00, for a total value of $340,556.00. Following the completion of the sale, the senior vice president owned 185,095 shares in the company, valued at $7,033,610. This trade represents a 4.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 6.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on AORT. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Needham & Company LLC decreased their price objective on Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 8th. LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research note on Friday, April 10th. Stifel Nicolaus set a $45.00 target price on Artivion in a research note on Monday. Finally, Canaccord Genuity Group reduced their price target on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.17.

Artivion Price Performance

NYSE:AORT opened at $21.05 on Tuesday. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The firm has a fifty day simple moving average of $31.64 and a 200 day simple moving average of $38.55. The stock has a market capitalization of $1.02 billion, a PE ratio of 87.73 and a beta of 1.27.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.